Patrick Hwu: Can an oncolytic virus be used to treat muscle invasive bladder cancer?
On November 9th, 2024, an article by Roger Li et al. was published in Nature Medicine.
Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial
Authors: Roger Li, Nancy Y. Villa, Xiaoqing Yu, Joseph O. Johnson, Gustavo Borjas, Jasreman Dhillon, Carlos M. Moran-Segura, Youngchul Kim, Natasha Francis, Denise Dorman, John J. Powers, Wade J. Sexton, Philippe E. Spiess, Michael A. Poch, Logan Zemp, Scott M. Gilbert, Jingsong Zhang, Julio M. Pow-Sang, Alexander R. A. Anderson, Tingyi Li, Xuefeng Wang, G. Daniel Grass, James M. Burke, Colin P. N. Dinney, Paulo C. Rodriguez, Rohit K. Jain, James J. Mulé, and Jose R. Conejo-Garcia
Patrick Hwu, President and CEO of Moffitt Cancer Center, shared the article on X, adding:
“Can an oncolytic virus be used to treat muscle invasive bladder cancer?
In this phase Ib study, Roger Li et al from Moffitt Cancer Center treated 21 cisplatin-ineligible muscle invasive bladder cancer patients with an intravesical oncolytic adenovirus expressing GM-CSF in combination with systemic anti-PD1 antibody in the neoadjuvant setting.
Pathologic complete response was seen in 42 percent of patients, and was associated with the formation of tertiary lymphoid structures in the tumor.
This is a promising strategy for Bladder Cancer and could one day lead to bladder sparing treatment options for these patients.”
Dr. Patrick Hwu, MD, currently serves as the President and CEO of Moffitt Cancer Center. With a focus on understanding the dynamics between tumors and the immune system, Dr. Hwu’s research has been pivotal in advancing gene-modified T cell therapy.
He notably contributed seminal work on the development of the first chimeric antigen receptor aimed at combating cancer. His research portfolio extends to vaccines, adoptive T-cell therapies, and mechanisms of immune resistance.Before joining, Dr. Hwu held numerous leadership roles at The University of Texas MD Anderson Cancer Center for over 17 years.
Notably, he served as the inaugural Chairman of the Department of Melanoma Medical Oncology in 2003, as well as the Associate Director of the Center for Cancer Immunology Research. Additionally, he chaired the Department of Sarcoma Medical Oncology, demonstrating his commitment to advancing cancer treatment and research.
Dr. Roger Li is a urologic oncologist at Moffitt Cancer Center, specializing in the surgical treatment of bladder, prostate, kidney, and penile cancers. He offers open, laparoscopic, and robotic-assisted procedures, including nerve-sparing options. Dr. Li received advanced training in urologic oncology at MD Anderson Cancer Center. Dr. Li researches personalized therapies through genomic profiling and develops new immunotherapies for early-stage bladder cancer.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023